Clinical trials have shown that immune checkpoint regulation therapies have good potential, although in many cases the effect is limited, especially in solid tumors with low response rates, probably because the majority of cancer patients are resistant to PD-1/PD-L1 blockade (41). The gene discussed is CD274; the disease is cancer.